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Background: Molluscum contagiosum is a common self-limiting viral infection of the skin. Many therapeutic agents have been used
with varying success rates. Objective: To evaluate and compare the eﬀectiveness of topical 10% KOH solution and 25% podophyllin solu-
tion as home-based treatments of molluscum contagiosum. Patients and methods: This open randomized comparative therapeutic trial
was conducted in the department of dermatology, Al-Yarmouk Teaching Hospital, Baghdad, Iraq between January and October 2015.
The patients were divided randomly into two equal groups. Group A patients were treated with 10% KOH solution and those in group B
with 25% podophyllin solution. All patients were assessed weekly for 4 weeks for therapeutic response. Results: Fifty-two patients (age:
2–34 years) with MC were enrolled in this study, 25 patients in group A and 20 patients in group B completed the study. Sixteen (64%)
patients in group A showed complete clearance of lesions versus 14 (70%) patients in group B. No systemic side eﬀects were reported in
both groups and the local side eﬀects were comparable between both groups. Conclusion: Both 10% KOH solution and 25% podophyllin
solution are eﬀective local therapies for the treatment of MC with comparable success rates (64% and 70% respectively).
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Molluscum contagiosum (MC) is a viral disease caused
by molluscum contagiosum virus (MCV) which is classiﬁed
within the Poxvirus family (Sterling, 2010). Approximatelyhttp://dx.doi.org/10.1016/j.jdds.2016.02.002
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Production and hosting by Elsevier1.8% of the population were aﬀected worldwide by MC
with a higher distribution in the tropical areas (Vos et al.,
2012). The disease is more prevalent in children (peak inci-
dence between 2 and 5 years) (Sterling, 2010; Hanson and
Diven, 2003). A later incidence peak in young adults is
attributable to sexual transmission with lesions more com-
mon in the genital area (Hanson and Diven, 2003). There is
a clinical impression that MC is more common in patients
with atopic eczema (Leslie et al., 2005). MCV is passed
directly by skin contact with an infected individual to
produce typical cutaneous and, rarely, mucosal lesions
(Dohil et al., 2006). The average incubation time is between
2 and 7 weeks with a range extending out to 6 months.
Infection with the virus causes acanthotic hyperplasiaehalf of King Saud University.
ommons.org/licenses/by-nc-nd/4.0/).
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lobes, each lobe made up of many lobules separated from
each other by distinct basement membrane (Sharquie
et al., 2015). Clinically the disease produces a papular erup-
tion of multiple umbilicated lesions. Individual lesions are
discrete, smooth, and dome shaped (Hanson and Diven,
2003). Any cutaneous surface may be involved, but favored
sites include the face, neck, abdomen, arms, thighs, axilla,
and genital areas (Bikowski, 2004). MC is a self-limited dis-
ease, which, left untreated, will eventually resolve in
immunocompetent hosts (Chen et al., 2013). In general,
there are four main therapeutic approaches to MC:
1. Physical therapies: like; cryosurgery (Silverberg, 2007),
evisceration (Hanson and Diven, 2003), phenol 10%
with pricking (Chen et al., 2013), curettage (Silverberg,
2007), tape stripping (Valentine and Diven, 2000), pho-
todynamic therapy (Chen et al., 2013), electron beam
therapy (Chen et al., 2013) and laser (Jones and
Muram, 1993; Binder et al., 2008).
2. Chemical destructive agents: like; trichloroacetic acid
(Chen et al., 2013), cantharidin (Chen et al., 2013), ben-
zoyl peroxide 10% (Chen et al., 2013), iodine solution
and salicylic acid (Valentine and Diven, 2000), tretinoin
(Rajouria et al., 2011), podophyllotoxin (Piggott et al.,
2012), podophyllin (Barefoot, 1951) and potassium
hydroxide (KOH) Romiti et al., 2000, 1999.
3. Immune modulators: like; imiquimod (Piggott et al.,
2012), diphencyprone (Chen et al., 2013), cimetidine
(Dohil and Prendiville, 1996) and intralesional candida
antigen (Chen et al., 2013).
4. Antiviral agents: like; cidofovir (Chen et al., 2013) and
subcutaneous IFN-a (Piggott et al., 2012).
The best way to prevent the spread of MC is through
good hygiene. (Centers for Disease Control and
Prevention, 2015)
Many therapeutic agents were used for the treatment of
MC with variable results. KOH in diﬀerent concentrations
has been well studied whereas podophylline solution, to
our best knowledge, wasn’t tried in the treatment of MC
except once. The aim of the present study was to evaluate
and compare the eﬀectiveness of topical 10% KOH solu-
tion and 25% podophyllin solution as home-based treat-
ments of molluscum contagiosum.
2. Patients and methods
An open comparative therapeutic study was conducted
in the Department of Dermatology and Venereology in
Al-Yarmouk Teaching Hospital, Baghdad-Iraq from 1st
of January 2015 to the end October 2015, where a total
number of 52 patients with MC were enrolled in this
study. The patients enrolled in this study were randomly
allocated into two groups through systematic random
sampling.A full history was taken from each patient regarding
name, age, sex, occupation, marital status, sexual history,
duration of the disease, family history of similar condition,
past medical history, drug history especially for corticos-
teroids and other immune suppressants and any previous
treatment modality received for their MCs.
Every patient was examined to assess the number, size
and site of lesions; examination was aided by taking several
photos for each patient using the same digital camera
(Canon Power Shot SX260HS Camera 12.1 Megapixel)
from approximately the same distance and similar view.
Patients excluded from this study included those with
face involvement to avoid any possible side eﬀect especially
of cosmetic concern, those who were previously treated,
pregnant and lactating women, uneducated (unreliable)
patient or his/her guardians and children less than 2 years
old.
An informed consent was obtained from each patient or
his/her parents prior to their inclusion in this study after
full explanation about the nature of the disease, its course
and prognosis and full information about therapeutic
agents intended to be used including the side eﬀects and
method of application were given. An approval of the
Ethics Committee of Scientiﬁc Council of Dermatology
and Venereology of Iraqi Board for Medical Specializa-
tions was also obtained.
2.1. Preparation of the therapeutic agents
A KOH powder (produced by Sinopharm Chemical
Reagent Co., Ltd., Shanghai, China) was dissolved in dis-
tilled water to produce a 10% w/v solution. A podophyllin
resin powder (produced by Baoji Oasier Bio-Tech Co., Ltd.
Baoji, China) was dissolved in tincture benzoin to produce
a 25% w/v solution.
2.2. Method of application
Patients in group A were treated with 10%KOH solution
and those in group B were treated with 25% podophyllin
solution with instructions given to the patients or their guar-
dians to apply the agent topically using cotton swab soaked
in the solution after covering the surrounding area with
petrolatum, making gentle application to the MC lesion
and avoid any spillage over normal skin. First application
of therapeutic agent was done in the outpatient clinic trying
to learn the patients the correct way of application and how
to use it at home. Patients in group A were asked to apply
10% KOH solution once daily at night and those in group
B were instructed to apply 25% podophyllin solution every
other night and wash oﬀ 4 h after application.
All patients were asked to attend weekly to the outpa-
tient clinic for evaluation and to use therapeutic agents
for 4 weeks or until the lesions are cleared, whichever was
early. The importance of regular attendance was stressed
upon to prevent defaulting.
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All patients were examined at the end of 1st, 2nd, 3rd,
and 4th weeks. On each visit the clinical response to treat-
ment; total disappearance of lesions, decrease in size and
number of lesions and any local or systemic side eﬀect were
evaluated and recorded depending on clinical and photo-
graphic assessments. Photographs for lesions were taken
before and after treatment.
The patients were considered as respondent when there
was complete disappearance of the lesion; if there was no
change, the patients were considered as non-respondent;
if there was decrease in the number and size of lesions,
the patients were considered as partial respondent.
If complete response occurred during treatment period,
they were asked to attend one month later to assess for any
recurrence of the lesion, if no response occurred, they were
considered as treatment failure.2.4. Statistical analysis
Data were coded and fed on a computer. Analysis was
done on SPSS (Statistical Package for Social ScienceAssessed for elig
Randomized
 Allocated to intervention A (n=26) 
Received allocated intervention (n=26) 
 Did not received allocated intervention 
(n=0) 
Alloca
 Lost to follow up due to non-
compliance (n=1)  
Discontinued intervention (n=0) 
Follow
Analyzed (n=25) 
Excluded from analysis (n=0) 
Analy
Enrollment 
Figure 1. Flowchart of participants’ proAnalysis, Version 21). Both a descriptive statistics like
mean and SD (Standard Deviation) together with analytic
statistics like Chi-square (v2) test and t-test have been done
when appropriate. P-Values less than 0.05 were considered
signiﬁcant. The results were presented in the form of fre-
quency table and graphs.3. Results
A total of 52 patients have been enrolled in this thera-
peutic trial. Patients were divided into two equal groups;
each consists of 26 patients. Out of a total of 52 patients
with MC, 25 patients in group A and 20 patients in group
B completed the study. In group A, one patient discontin-
ued the treatment due to noncompliance, and in group B,
six patients did not complete the study, one of them didn’t
tolerate the local irritation caused by therapeutic agent he
used while others due to noncompliance (Fig. 1).
The age of patients ranged from 2 to 34 years, with a
mean ± SD of 10.84 ± 9.02 years, the youngest patient
was 2 years old and the oldest one was 34 years old. The
males outnumbered females (28 vs. 17) with a male to
female ratio 1.6:1. The two groups were well-matched inibility (n=60) 
Excluded (n=8) 
Not meeting inclusion criteria (n=5) 
Declined to participate (n=3) 
 (n=52) 
 Allocated to intervention B (n=26) 
Received allocated intervention 
(n=26) 
 Did not received allocated 
intervention (n=0) 
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Discontinued intervention due to 
severe local irritation caused by 
therapeutic agent used (n=1) 
-up 
   Analyzed (n=21) 
-1 excluded from analysis due to 
missing data 
sis 
gress through the phases of the trial.
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no signiﬁcant variation between them in terms of age and
gender (Table 1).
The duration of the disease among all patients ranged
from 2 weeks to 6 months and a family history of MC
was positive in 18 out of the 45 patients (40%).
The number of lesions per patient ranged from 1 to 75
lesions with a mean ± SD of 8.95 ± 9.32 lesions and the
total number of lesions was 403 lesions. Thirty-nine
(86.6%) patients had 1–15 lesions, 4 (8.9%) patients had
16–30 patients and 2 patients had more than 30 lesions.
At the end of the study, 16 (64%) out of 25 patients in
group A showed complete clearance of lesions [181
(82.3%) lesions out of 220], while cases in group B showed
total clearance of lesions in 14 (70%) out of 20 patients with
143 (78.1%) lesions out of 183 (Table 2). The results of both
groups were comparable and there was no signiﬁcant diﬀer-
ence between them (P-value > 0.67). The time needed for
complete clearance of MC lesions in both groups ranged
from 1 to 4 weeks (Table 3). Therapeutic response for both
10% KOH solution and 25% podophyllin solution is shown
in (Figs. 2–5).
During the study period no systemic side eﬀect in both
groups was encountered whereas local side eﬀects were
reported in 72% and 75% in group A and group B respec-
tively (Table 4).
At follow up visit (one month after stopping the
treatment), 5 (25%) out of 20 patients used podophyllinTable 1
The frequency distribution of patients with molluscum contagiosum according
Age (Year) Group A
Male No. (%) Female No. (%) Total No. (%)
2–10 11 (44) 7 (28) 18 (72)
11–20 3 (12) 0 (0) 3 (12)
21–30 3 (12) 0 (0) 3 (12)
P31 0 (0) 1 (4) 1 (4)
Total* 17 (68) 8 (32) 25 (100)
Site Group A Group B
No. of Patients Lesions No. and (%) No. of Patients
Genitalia 5 99 (45) 5
Trunk 17 90 (41) 10
Extremities 11 31 (14) 9
Total** 220 (100)
* Group A (mean ± SD = 9.56 ± 9.22) years. Group B (mean ± SD = 12.45
** Group A (mean ± SD of 8.8 ± 11.33) lesions. Group B (mean + SD of 9.1
Table 2
Scores of therapeutic response in the patients with MC in both groups (A) an
Scores of response Group A
No. and (%) of patients No. and (%) of
Complete clearance 16 (64) 181 (82.3)
Partial clearance 4 (16) 23 (10.4)
No response 5 (20) 16 (7.3)
Total 25 (100) 220 (100)
According to the number of patients P-value > 0.671, Chi Square = 0.18
According to the number of lesions P-value > 0.298, Chi Square = 1.08treatment developed new lesions whereas new lesions were
seen in 2 (10%) out of 25 patients who were treated with
KOH solution at new sites other than those previously
involved. No recurrence of any treated lesions in patients
of both groups could be detected.
All side eﬀects were transient and lasted just few weeks
and had totally disappeared.
4. Discussion
In last few years, MC seems to be so common among
Iraqi patients especially children and a large proportion
of those patients or their guardians seek a suitable therapy
which is asked to be non-painful, non-disﬁguring and with
an acceptable cost. Many topical therapeutic agents had
been tried in the treatment of MC with variable success
rates, these included: phenol solution with a success rate
(clearance of lesions) of (41%) Chen et al., 2013, TCA solu-
tion (60%) Goyal et al., 2014, salicylic and lactic acids
(100%) Kӧse et al., 2013, cantharidin (23%) Chen et al.,
2013, benzoyl peroxide (Chen et al., 2013), tretinoin
(45%) Goyal et al., 2014, diphencyprone (64%) Kang
et al., 2005, cidofovir (93%) Hanson and Diven, 2003;
Chen et al., 2013, podophyllotoxin (92%) Markos, 2001,
and imiquimod (75–82%) Seo et al., 2010.
Since 1999, KOH solution in diﬀerent concentrations
(2.5–20%) is tried in the treatment of MC (Romiti et al.,
1999; Kӧse et al., 2013; Mahajan et al., 2003; Uc¸makto the age, gender and sites of lesions.
Group B
Male No. (%) Female No. (%) Total No. (%)
7 (35) 6 (30) 13 (65)
0 (0) 1 (5) 1 (5)
4 (20) 2 (10) 6 (30)
0 (0) 0 (0) 0 (0)
11 (55) 9 (45) 20 (100)
Total
Lesions No. and (%) No. of Patients Lesions No. and (%)
60 (32.8) 10 159 (39.5)
65 (35.4) 27 155 (38.5)
58 (31.8) 20 89 (22)
183 (100) 403 (100)
± 8.73) years. P-Value > 0.284. Total (mean ± SD of 10.84 ± 9.02) years.
5 ± 5.90) lesions. Total (mean ± SD of 8.95 ± 9.32) lesions.
d (B) at the end of 4th week of treatment.
Group B
lesions No. and (%) of patients No. and (%) of lesions
14 (70) 143 (78.1)
4 (20) 31 (16.9)
2 (10) 9 (4.9)
20 (100) 183 (100)
Table 3
Time needed for complete clearance of MC lesions in both groups.
Duration of treatment Group A Group B
No. and (%) of patients No. and (%) of lesions No. and (%) of patients No. and (%) of lesions
1 week 1 (6.25) 1 (0.5) 3 (21.4) 20 (14)
2 weeks* 9 (56.25) 106 (58.6) 5 (35.7) 41 (28.7)
3 weeks 3 (18.75) 24 (13.3) 4 (28.6) 67 (46.8)
4 weeks 3 (18.75) 50 (27.6) 2(14.3) 15 (10.5)
Total 16 (100) 181 (100) 14 (100) 143 (100)
* Within two weeks of treatment: P-value < 0.00, Chi Square = 8.67
B A 
Figure 2. A photograph showing disappearance of MC lesions in a patient treated with 25% podophyllin solution. (A) Before treatment, (B) After 2 weeks
of treatment.
BA 
Figure 3. A photograph showing complete clearance of huge number of MC lesions in a patient treated with 25% podophyllin solution. (A) Before
treatment, (B) after 4 weeks of treatment.
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et al. (1999) reported a full remission in 32 out of the 35
(91.4%) patients treated with 10% KOH solution in an
average of 30 days. The same researchers carried out in
the year 2000 another study trying 5% KOH solution and
claimed a (100%) remission rate in an average of six weeks(Romiti et al., 2000). Short et al in 2006 treated 10 patients
with 10% KOH solution in a placebo-controlled study and
they found 70% clearance rate for KOH versus 20% for the
placebo (Short et al., 2006). Also Can et al. (2014) treated
40 children with MC with 10% KOH solution but with
twice daily application and they reported (92.5%) clearance
BA
Figure 4. Disappearance of MC lesions in a patient treated with 10% KOH solution, (A) before treatment, (B) after 4 weeks of treatment.
BA 
Figure 5. Disappearance of MC lesions in a patient treated with 10% KOH solution, (A) before treatment, (B) after 4 weeks of treatment.
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treated 25 patients with MC comparing (2.5% and 5%)
KOH solution for 2 months, they found signiﬁcant diﬀer-
ence between the success rates (23.1% and 66.7% respec-
tively). Mahajan et al. (2003) treated 27 patients with
20% KOH solution. All treated children were cleared of
their lesions within 17 days of treatment. However, stinging
sensation and postinﬂammatory pigmentation were fre-
quent side eﬀects.
Our result regarding 10% KOH solution in the treat-
ment of MC seems to be comparable with previousmentioned studies that used same concentration of KOH
and similar duration of treatment (Kang et al., 2005;
Mahajan et al., 2003; Short et al., 2006).
Regarding podophyllin trials in MC, for our best knowl-
edge and search, only came across only one study dating to
1949 done by Barefoot at al. They reported only 3 patients
treated with topical application of 20% podophyllin and all
of them were cured. They considered it as a safe home ther-
apy but requires reliable patients (Barefoot, 1951). We have
found a success rate of 70% of patients treated with 25%
podophyllin solution.
Table 4
Comparison of local side eﬀects noticed in both group (A) and (B).
Side eﬀects Group (A) No. and (%) of patients Group (B) No. and (%) of patients
Burning 18 (72) 12 (60)
Erythema 11 (44) 13 (65)
Erosion 12 (48) 7 (35)
Hyperpigmentation 16 (64) 11 (55)
Hypopigmentation 3 (12) 2 (10)
Itching 7 (28) 3 (15)
Total patients with adverse eﬀects 18 (72) 15 (75)
P-Value > 0.684
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and 25% podophyllin solutions to be eﬀective in the treat-
ment of MC with comparable results. In terms of the num-
ber of patients cured podophyllin was slightly better than
KOH solution (70% versus 64%) with non-signiﬁcant sta-
tistical diﬀerence (P > 0.67); while in terms of the number
of lesions cleared oﬀ the reverse was true (KOH 82% versus
podophyllin 78%) and also with non-signiﬁcant diﬀerence
statistically (P > 0.29).
Many local side eﬀects especially erythema, burning sen-
sation and dyspigmentation were seen in both groups of
patients enrolled in this study. Although the frequency of
these local side eﬀects was slightly higher among patients
treated with podophyllin (75% versus 72%), however the
diﬀerence was statistically insigniﬁcant (P > 0.68). All
reported local adverse eﬀects were mild and transient and
disappeared spontaneously shortly after the end of treat-
ment except one patient who suﬀered severe local irritation
caused by podophyllin that prevented him from continuing
the treatment due to intolerability. Most of these local side
eﬀects are similarly reported in many other studies
(Barefoot, 1951; Romiti et al., 2000, 1999; Kӧse et al.,
2013; Mahajan et al., 2003; Uc¸mak et al., 2014; Can
et al., 2014; Short et al., 2006). Fortunately, neither sys-
temic side eﬀects nor local scarring were encountered dur-
ing this study.5. Conclusion
Both 10% KOH solution and 25% podophyllin solution
are eﬀective local therapies for the treatment of MC with
comparable success rates (64% and 70% respectively).
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